Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

Status Withdrawn

Clinical Trial Summary

This is an observation study comparing prospective use of Imipenem/Cilastatin/Relebactam (IMI/REL) to retrospective data using Meropenem/Vabobactam (MVB)and Ceftazidime/Avibactam CZA) in treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae infections at a tertiary care hospital. The objectives of the study are to demonstrate successful treatment of KPC containing Enterobacteriaceae infections with IMI/REL including in bacteremia, and to analyze treatment outcomes in use of IMI/REL for KPC-producing infections compared to historical clinical outcome data with CZA and MVB use at the same institution.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Antibiotic Resistant Infection
Bacterial Infections
Carbapenem-Resistant Enterobacteriaceae Infection
Communicable Diseases
Enterobacteriaceae Infections
Gram-Negative Bacterial Infections
Infections
KPC

Clinical Trial Details

NCT number	NCT04785924
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact
Status	Withdrawn
Phase	Phase 4
Start date	June 7, 2021
Completion date	January 12, 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT03309358` - A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis	Phase 1
Recruiting	`NCT02922998` - CD64 and Antibiotics in Human Sepsis	N/A
Completed	`NCT04212403` - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB)	N/A
Recruiting	`NCT05502380` - Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery	Phase 3
Not yet recruiting	`NCT04462133` - Optimal Tailored Treatment for H. Pylori Infection	N/A
Completed	`NCT03535324` - Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT)	N/A
Recruiting	`NCT05950984` - Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
Withdrawn	`NCT04230746` - Effect of Antibiotics on Urinary Microbiome	Early Phase 1
Active, not recruiting	`NCT03865706` - Inulin for Infections in the Intensive Care Unit	Phase 2
Not yet recruiting	`NCT06028217` - Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
Recruiting	`NCT05391035` - The Antibiotic Guardian Study- Clinical Evaluation of a Novel, Rapid Diagnostic for Gonorrhoea and Mycoplasma Infections.
Recruiting	`NCT05224401` - Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs	Phase 3
Not yet recruiting	`NCT03855709` - Antibiotic-resistant Bacterial Infection of Hepatic Patients
Terminated	`NCT03535272` - Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea	Phase 3
Recruiting	`NCT05902299` - Evaluation of the Impact of the Modification of Antibiotic Susceptibility Testing on Antibiotic Prescriptions
Recruiting	`NCT05293483` - The Impact of Covid-19 Hospital Care on the Prevalence of MDRO in Indonesia
Recruiting	`NCT05561504` - Helicobacter Pylori Local Prevalence and Antibiotic Resistance
Recruiting	`NCT03606031` - Digestive Microbiota Transplant
Completed	`NCT01573195` - Merck IISP Stewardship Grant for Antibiotic Best Practices	Phase 4
Not yet recruiting	`NCT03857295` - Infections Following NeuroSurgery (INS)